GTCR, a private equity firm focused on leveraged buyout, agreed to acquire Surmodics, a provider of surface modification technologies for intravascular medical devices and a provider of chemical components for in vitro diagnostic, for $627m. “We are pleased to announce this transaction, which enables Surmodics shareholders to realize immediate value creation with a substantial premium, reflecting the significant progress and important achievements made by our employees. GTCR is an ideal partner for Surmodics, given its extensive history and deep domain expertise in the Healthcare sector, and I am confident that this transaction will position the company to continue to deliver compelling benefits for physicians, patients and customers going forward,” Gary Maharaj, Surmodics President and CEO.